Inflammasome Therapeutics is focused on developing therapies for degenerative diseases such as Alzheimer’s disease, multiple sclerosis, macular degeneration, and Parkinson's disease.

Inflammasome Therapeutics

Inflammasome Therapeutics | 341 followers on LinkedIn. Cutting edge treatment for eye diseases and more | Inflammasome Therapeutics is a science based company founded to develop therapies for prevalent, degenerative diseases such as Alzheimer’s disease, multiple sclerosis, macular degeneration, and Parkinson&#39;s disease.

President and CEO at Inflammasome Therapeutics, Ltd.

Paul Ashton

Inflammasome Therapeutics marks the second clinical trial underway with their new drug. Great things are happening at Inflammasome.

Inflammasome Therapeutics announces first patient dosed in Phase 1 Diabetic Macula Edema Study of the Dual Inflammasome Inhibitor K8

Inflammasome Therapeutics has received FDA approval to launch a phase 1/2 first-in-class clinical trial that will evaluate its investigational drug candidate for the treatment of geographic atrophy (GA). Learn more on Glance: https://lnkd.in/gwfYfHbP #GlanceNews Marty Nazzaro LeBlanc Ron

INFL

COM:INFLAM

Inflammasome Therapeutics

locale

market

industry

website

linkedin

peer of

Metrics